BULK-FIBER-NETWORKS
24.3.2022 09:02:03 CET | Business Wire | Press release
Aqua Comms , a leading provider of network connectivity services, Bulk Fiber Networks, a leading builder and operator of fiber network infrastructure, and Meta have completed the construction of the Havhingsten cable system. A fully funded project, the parties have contracted with Alcatel Submarine Networks (“ASN”) to build the subsea cable, which will bring greater connectivity in Europe and the Nordics.
This new route represents true diversity avoiding congested paths across the English Channel and offers resilient network architecture options for enterprises, carriers and hyperscalers whilst delivering the lowest latency available between Dublin and the Nordic region.
The Havhingsten cable system showcased several key innovations and technological milestones throughout its design and construction.
Firstly, Havhingsten is the world’s first aluminum conductor powered subsea cable system. As a material, aluminum allows for a much lower cable conductor voltage drop, which ultimately allows for a higher number of fiber pairs per cable. To achieve such innovative solutions requires investment in technology and close collaboration with partners and vendors. The removal of traditional copper raw material and replacement with aluminum from the manufacturing process benefits the overall system in efficiency and cost reduction, as copper is associated with variable availability and higher price. Additional benefits include, lighter aluminum allows more cable to be loaded onto an installation vessel and improved resistance to hydrogen penetration, an element which is unfavorable to the operation of optical fiber in ocean waters.
Secondly, the end-to-end system combines data transmission seamlessly across both an unrepeatered subsea segment in the Irish Sea, a terrestrial segment in the UK and a repeatered segment in the North Sea. Typical systems have one or two of these elements, but not all three.
Lastly, the system utilized a new enhanced, jet-assisted burial plough in both the North and Irish Sea segments, allowing the installers of the system to bury the cable to our specific demanding level of protection in very challenging seabed conditions along the route.
About Aqua Comms:
Aqua Comms is a leading provider of global subsea connectivity services delivered through an extensive portfolio of owned and operated subsea systems. Aqua Comms offers connectivity networking solutions including managed capacity services, spectrum and dark fibre to the global content, cloud and carrier markets.
To learn more about Aqua Comms and its portfolio of connectivity networking solutions visit www.aquacomms.com
In April 2021, Aqua Comms DAC was acquired by Digital 9 Infrastructure plc (D9), an LSE listed investment trust managed by Triple Point Investment Management LLP.
D9 is a digital infrastructure investment trust that has raised over US$ 1.1 billion since its IPO in March 2021, investing into data centres and fibre networks. Its team has over US$ 300 billion transactional and operational experience in digital infrastructure. The number 9 in Digital 9 Infrastructure comes from the UN Sustainable Development Goal number 9, which focuses the fund on investments that bridge the digital divide by increasing connectivity globally and that improve the environmental sustainability of digital infrastructure.
To learn more about D9 visit www. https://www.d9infrastructure.com
About Bulk Fiber Networks
Bulk Fiber Networks is a leading builder and operator of fiber network infrastructure, tailor-made to meet the growing demands of large-scale data and cloud service providers in the Nordics, the US and Europe. We offer some of the shortest, lowest-latency international and intra-Nordic fiber routes available. To learn how Bulk Fiber Networks can help you connect into the Nordics, visit bulkinfrastructure.com and follow us on LinkedIn , Twitter and Facebook . Bulk Fiber Networks is a division of Bulk Infrastructure, a leading provider of sustainable digital infrastructure in the Nordics.
About Meta
Meta builds technologies that help people connect, find communities, and grow businesses. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram and WhatsApp further empowered billions around the world. Now, Meta is moving beyond 2D screens toward immersive experiences like augmented and virtual reality to help build the next evolution in social technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005021/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom